Effects of magnetic resonance imaging prognostic factors on neoadjuvant therapy in T3 or N+ rectal cancer: A retrospective cohort study-Reference-Cited by-全球学者库

Effects of magnetic resonance imaging prognostic factors on neoadjuvant therapy in T3 or N+ rectal cancer: A retrospective cohort study

Published:2023-12 Issue:4 Volume:16 Page:442-445
ISSN:1756-5383
Container-title:Journal of Evidence-Based Medicine
language:en
Short-container-title:J Evidence Based Medicine

Author:

Xie Hao¹²³,Zeng Ziwei¹²³,Cai Yonghua¹²³,Ma Decai⁴,Lei Dongxu¹²³,Ye Fujin¹²³,Luo Shuangling¹²³,Xiong Li¹²³,Li Wenxin¹²³,Liang Zhenxing¹²³,Zheng Xiaobin¹²³,Huang Liang¹²³,Liu Huashan¹²³⁵,Kang Liang¹²³^ORCID

Affiliation:

1. Department of General Surgery (Colorectal Surgery) The Sixth Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong China

2. Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases The Sixth Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong China

3. Biomedical Innovation Center The Sixth Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong China

4. Department of Radiology The Sixth Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong China

5. Guangdong Provincial Key Laboratory of Digestive Cancer Research The Seventh Affiliated Hospital, Sun Yat‐sen University Shenzhen Guangdong China

Funder

National Natural Science Foundation of China

Basic and Applied Basic Research Foundation of Guangdong Province

China Postdoctoral Science Foundation

Publisher

Wiley

Subject

Health Policy,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jebm.12567

Reference15 articles.

1. A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

2. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

3. Colorectal cancer: summary of NICE guidance

4. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

5. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial